Business Context and Reporting Period
Company: TNF Pharmaceuticals, Inc. (TNFA)
Filing Type: Form 8-K (Current Report)
Reporting Date: September 4, 2025
Principal Executive Offices: New York, NY
This filing reports the closing of a private placement, the acquisition of a subsidiary, and amendments to existing preferred stock agreements.
Key Financial Metrics and Transactions
The filing details capital raising and acquisition activities rather than standard operating financial metrics (revenue, profit, cash flow). Key transaction values include:
- Series H Private Placement: Sale of 7,000 shares of Series H Convertible Preferred Stock with a stated value of $1,000 per share (Total Stated Value: $7,000,000).
- Conversion Terms (Series H): Initially convertible into up to 1,400,000 shares of Common Stock at $5.00 per share.
- Warrants Issued: Warrants to acquire up to 1,400,000 shares of Common Stock at an exercise price of $5.00 per share.
- Acquisition (LPU Holdings LLC): Acquisition of 100% membership interests in LPU Holdings LLC.
- Acquisition Consideration: Issuance of Series I Convertible Preferred Stock convertible into 747,362 shares of Common Stock.
Note: The filing text does not provide clear values for revenue, net income, operating cash flow, or total debt levels.
Material Changes vs. Prior Period
The filing reports significant structural changes to the company's capitalization and debt obligations:
- Series F and F-1 Preferred Stock Amendments:
- Maturity dates extended to March 2, 2027.
- Amortization payments and related terms/covenants removed.
- New Equity Instruments: Creation and issuance of Series H and Series I Convertible Preferred Stock.
- Asset Acquisition: Addition of LPU Holdings LLC to the company's portfolio.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the successful closing of the transactions previously announced on September 2, 2025. A press release regarding the closing is attached as Exhibit 99.1.
Risks and Contingencies:
- Dilution: The issuance of Series H and Series I preferred stock introduces potential dilution to existing common shareholders upon conversion (total potential conversion of 2,147,362 shares).
- Regulatory Status: The registrant is not an emerging growth company.
- Forward-Looking Statements: Information in the press release (Exhibit 99.1) is not deemed "filed" for Section 18 liability purposes.
The filing text does not provide specific financial guidance, revenue outlook, or detailed risk factors beyond the transactional implications.
Investor Verification Checklist
- Verify the full text of the Series H and Series I Certificates of Designations (Exhibits 3.1 and 3.4) for specific liquidation preferences, dividend rights, and voting powers.
- Review the Second Amended and Restated Certificates for Series F and F-1 (Exhibits 3.2 and 3.3) to confirm the removal of amortization obligations and the new maturity date.
- Examine the Press Release (Exhibit 99.1) for additional context on the use of proceeds from the Series H placement.
- Confirm the conversion limitations applicable to the Series I stock issued for the LPU acquisition.